GlobeNewswire

Expanding Global Deployments of Product Cost Management Drive New Capabilities in Latest Release

Dela

New Simulation-Driven Design Features in aPriori Professional 2018 R1 Help Improve Product Profitability & Accelerate Time to Market

 

CONCORD, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- aPriori, the leading provider of automated product cost management (PCM) software and service solutions for global manufacturers, today announced the newest release of the company's flagship product, aPriori Professional 2018 R1.

This new release concentrates on helping manufacturers combat some of the most critical challenges they are facing in their businesses today, including:

  • Aerospace manufacturers are struggling with how to accommodate fixed price contracts and maintain profitability in an environment where new materials and manufacturing processes are being introduced continuously.
  • Automotive manufacturers are struggling with major platform redesigns that are required to meet the demand for new electrified and autonomous vehicles.
  • Industrial Machinery manufacturers are faced with new competition from more nimble start-up competitors in low cost countries that continue to put pressure on bringing new innovations to market faster.
  • Electronic & High Tech product manufacturers are facing extreme challenges to bring innovative products to market faster requiring near perfect collaboration with their Contract Manufacturing partners who face their own challenges generating accurate quotes for new product designs in a timely manner.

Highlights of aPriori Professional 2018 R1

With aPriori 2018 R1, the company continues its commitment to helping customers overcome these challenges using time-proven product cost management business strategies and the world's most advanced PCM technology platform.  The primary highlights of this release include:

  • aPriori 2018 R1 has been extended to more easily integrate into engineering automation tools that support a Design of Experiments to simultaneously optimize product designs for performance and cost.
  • Continued advances have been made in the area of Design to Cost / Design for Manufacturability features so that engineering can quickly and easily get cost and manufacturability feedback early in the design process to eliminate late stage rework and product launch delays.
  • aPriori 2018 R1 also features significant upgrades to the Additive Manufacturing cost model, enabling end users to compare traditional subtractive manufacturing processes and additive manufacturing approaches.  Specifically, aPriori now supports Direct Metal Laser Sintering (DMLS) which is often used to make metal parts in aerospace, industrial and medical industries. 
  • With aPriori 2018 R1, a new Stretch Forming cost model is being introduced.  This manufacturing technique is commonly used in aerospace manufacturers to make large multi-curvature parts with low production rates, such as empennage, wing, fuselage and nacelle components on an airplane.
  • aPriori is one of the pioneers responsible for providing quick, automated costing from 3D solid CAD models. In aPriori 2018 R1, aPriori continues its pioneering work in automated design model costing by introducing support for costing of surface models.  Surface models are still used extensively for complex sheet metal parts particularly in the automotive industry.

The items above represent a fraction of the new capabilities delivered in aPriori 2018 R1.  Hundreds of additional enhancements have been implemented in the product's core Sheet Metal, Sand Casting, Plastic Molding and Bar & Tube cost models, many of which were driven through our collaboration with our expanding customer base.  For a complete list of new features available with aPriori 2018 R1, customers can refer to our Release Notes in the HelpCenter.  An aPriori Support system password is required to access this documentation.

Watch a 2 Minute Video of aPriori 2018 R1 DTC/DFM Capabilities

Enhanced Costing Capabilities for Printed Circuit Board Assembly

With this new release, aPriori continues to upgrade its capabilities around costing the assembly of Wire Harnesses and Printed Circuit Boards.  Through a collaborative process with strategic industry partners, aPriori has implemented the following improvements to our electrical/electronics cost models:

  • Performance - costing times are reduced by approximately 50-70% for PCBA and Wire Harness
  • Improved Manufacturing Analysis - aPriori 2018 R1 includes numerous updates throughout both modules to better align with real world manufacturing practices
  • Workflow - this new release provides better control over which components are used from the component library; users now specify which supplier or manufacturer they want to use for each component as well as having direct control over the purchase quantity assumptions

Watch an Overview of Our Enhanced PCBA Solution

"Our growing customer base in aerospace, automotive, industrial machinery, and electronics markets are facing some extreme challenges in bringing their products to market faster and at target cost.  This latest release of aPriori represents another big step forward in our efforts to provide cost and manufacturability guidance for our customers," reported Julie Driscoll, Vice President of Strategic Marketing and Product Management.  "Our PCM technology platform is highly unique in that it supports the entire design to delivery process.  Our company was founded on the principle that each day designers, buyers, cost engineers, manufacturing engineers and department leaders are making tradeoff decisions that have a significant impact on product profitability.  aPriori 2018 R1 continues our commitment to providing cost solutions that allow individuals across the entire product lifecycle to understand the cost impact of these decisions - at the exact moment they are making those decisions."

About aPriori
aPriori software and services generate hard-dollar product cost savings for discrete manufacturing and product innovation companies. Using aPriori's real-time product cost assessments, employees in engineering, sourcing and manufacturing make more-informed decisions that drive costs out of products pre- and post-production. With aPriori, manufacturers launch products at cost targets, maximize savings in re-work projects and avoid overpaying for sourced parts.  To learn more about aPriori and its product cost management solutions and services, visit www.apriori.com or call 1.978.371.2006.

aPriori on Twitter @aPriori_Inc. 
aPriori on XING https://www.xing.com 
Enterprise Product Costing Blog

aPriori and aPriori Technologies are registered trademarks of aPriori Technologies Inc. All other trademarks, registered trademarks or service marks belong to their respective holders.

CONTACT:
Rick Burke
Vice President, Marketing
rburke@apriori.com
978.451.7675



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: aPriori Technologies via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum